Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) FCF Margin (2018 - 2025)

Historic FCF Margin for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to 101.06%.

  • Arcturus Therapeutics Holdings' FCF Margin fell 438400.0% to 101.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 60.09%, marking a year-over-year decrease of 216700.0%. This contributed to the annual value of 39.65% for FY2024, which is 270600.0% down from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' FCF Margin stood at 101.06%, which was down 438400.0% from 20.33% recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' FCF Margin ranged from a high of 479.64% in Q2 2023 and a low of 2030.47% during Q1 2021
  • Its 5-year average for FCF Margin is 345.52%, with a median of 73.96% in 2023.
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' FCF Margin crashed by -15724200bps in 2021 and then soared by 15245300bps in 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' FCF Margin (Quarter) stood at 752.76% in 2021, then soared by 113bps to 97.6% in 2022, then tumbled by -105bps to 4.87% in 2023, then surged by 74bps to 1.25% in 2024, then crashed by -8001bps to 101.06% in 2025.
  • Its FCF Margin was 101.06% in Q3 2025, compared to 20.33% in Q2 2025 and 120.06% in Q1 2025.